Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3114262 | 0.92 | MAPK14 (0.46) | MAPK14TP53 | |
| SCHEMBL3115360 | 0.92 | MAPK14 (0.49) | MAPK14TP53 | |
| SCHEMBL3115455 | 0.91 | MAPK14 (0.51) | MAPK14TP53 | |
| SCHEMBL3120717 | 0.90 | MAPK14 (0.58) | MAPK14TP53 | |
| SCHEMBL3115880 | 0.89 | MAPK14 (0.49) | MAPK14TP53 | |
| SCHEMBL3103648 | 0.87 | MAPK14 (0.51) | MAPK14TP53 | |
| SCHEMBL3118662 | 0.84 | MAPK14 (0.51) | MAPK14 | |
| SCHEMBL3121346 | 0.83 | MAPK14 (0.49) | MAPK14 | |
| SCHEMBL3115999 | 0.82 | MAPK14 (0.59) | MAPK14 | |
| SCHEMBL3106203 | 0.82 | MAPK14 (0.61) | MAPK14TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101980609-B | B-ring reduced-D-ring oxidized tetrapyrrole photosensitizers for photodynamic therapy and tumor imaging | 健康研究有限公司 | 2016-10-19 | — | — | CN | claimed |
| CN-101980609-A | B-ring reduced-D-ring oxidized tetrapyrrole photosensitizers for photodynamic therapy and tumor imaging | HEALTH RESEARCH INC | 2011-02-23 | — | — | CN | claimed |
| US-20100256120-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB | 2010-10-07 | — | — | US | claimed |
| EP-4424304-A1 | METHOD FOR PREPARING MEDICINES, HAVING REDUCED PRODUCTION TIME AND IMPROVED STABILITY | Dr.Inb Co. (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-118215473-A | Method for manufacturing medicine with shortened production time and improved stability | INB博士有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20230243810-A1 | COMPOSITION AND METHOD FOR MODULATING FIBROBLAST GROWTH FACTOR RECEPTOR 3 ACTIVATION | ACADEMIA SINICA (TW) | 2023-08-03 | — | — | US | disclosed |
| WO-2023085567-A1 | METHOD FOR PREPARING MEDICINES, HAVING REDUCED PRODUCTION TIME AND IMPROVED STABILITY | 닥터아이앤비(주) | 2023-05-19 | — | — | WO | disclosed |
| US-11630102-B2 | Composition and method for modulating fibroblast growth factor receptor 3 activation | ACADEMIA SINICA (TW) | 2023-04-18 | — | — | US | disclosed |
| CN-110314136-B | Preparation and application of tumor targeting drug based on unsaturated fatty acid nanoparticles | 华南师范大学 | 2021-07-27 | — | — | CN | disclosed |
| WO-2018148376-A1 | COMPOSITION AND METHOD FOR MODULATING FIBROBLAST GROWTH FACTOR RECEPTOR 3 ACTIVATION | SHIH, MING-CHE (US) | 2018-08-16 | — | — | WO | disclosed |
| CN-101980609-B | B-ring reduced-D-ring oxidized tetrapyrrole photosensitizers for photodynamic therapy and tumor imaging | 健康研究有限公司 | 2016-10-19 | — | — | CN | disclosed |
| CN-101980609-A | B-ring reduced-D-ring oxidized tetrapyrrole photosensitizers for photodynamic therapy and tumor imaging | HEALTH RESEARCH INC | 2011-02-23 | — | — | CN | disclosed |
| US-20100256120-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB | 2010-10-07 | — | — | US | disclosed |
| US-20100256136-A1 | Method for Enhancing Pdt Efficacy Using a Tyrosine Kinase Inhibitor | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-10-07 | — | — | US | disclosed |
| US-20090155875-A1 | Methods to Enhance Carbon Monoxide Dehydrogenase Activity and Uses Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008008215-A2 | METHOD FOR ENHANCING PDT EFFICACY USING A TYROSINE KINASE INHIBITOR | HEALTH RESEARCH, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2006089206-A9 | METHODS TO ENHANCE CARBON MONOXIDE DEHYDROGENASE ACTIVITY AND USES THEREOF | MASSACHUSETTS INST TECHNOLOGY (US) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006089206-A2 | METHODS TO ENHANCE CARBON MONOXIDE DEHYDROGENASE ACTIVITY AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256120-A1 | AMIDE DERIVATIVES | IL1B, IL1A, IL6 | MAPK14 2363/4885TP53 1524/4885 |
| US-20100256136-A1 | Method for Enhancing Pdt Efficacy Using a Tyrosine Kinase Inhibitor | UROD, SLC7A1, TAP2 | MAPK14 574/4885TP53 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.